Heart transplantation remains as the ultimate treatment for end-stage heart failure. Numerous and diverse stem cell therapies have failed to succeed in clinical trials. Protocol variations among labs should be reduced before planning new animal studies. A unifying flowchart is presented as a suggestion for future studies. Biofluid molecular monitoring should be included to evaluate therapeutic success.